what is gip in tirzepatide Molecular structure of and the dual activation mechanism of Tirzepatide Pharmacodynamics in Research Studies

CT-388's compound patents run to approximately 2040-2041 (US), creating a five-year exclusivity window as the sole branded dual GLP-1R/GIPR agonist after tirzepatide faces generic entry

If not, then why is there extra medication in the pen to begin with

The reduction of cardiovascular disease does not decrease medical claims to the point where it is more financially beneficial to include the GLP-1s on the drug formularies because the claims resulting from the medication alone are higher than the claims related to cardiovascular treatments

By day four or five after the injection, many people find their energy returns to normal